Suppr超能文献

放射性造影剂相关性肾功能障碍:低渗造影剂与传统高渗造影剂的比较

Radiocontrast-associated renal dysfunction: a comparison of lower-osmolality and conventional high-osmolality contrast media.

作者信息

Lautin E M, Freeman N J, Schoenfeld A H, Bakal C W, Haramati N, Friedman A C, Lautin J L, Braha S, Kadish E G

机构信息

Department of Radiology, Montefiore Medical Center, Bronx, NY 10467.

出版信息

AJR Am J Roentgenol. 1991 Jul;157(1):59-65. doi: 10.2214/ajr.157.1.2048540.

Abstract

Nephropathy is an established untoward event associated with intravascular administration of conventional high-osmolality contrast media (HOM). It has not been shown previously that lower-osmolality contrast media (LOM) are less nephrotoxic in a clinical setting. We evaluate the ability to replace HOM with LOM (in lower-extremity angiography) to reduce the incidence of nephropathy. We use multiple definitions for contrast-induced nephropathy (six different magnitudes of rise of serum levels of creatinine or blood urea nitrogen in various periods). The incidences of nephrotoxic effects with LOM vs HOM in patients with presumed risk factors, including preexisting renal insufficiency and diabetes, are evaluated also. When all patients are considered, the incidence of contrast-induced nephropathy for LOM vs HOM (defined as an increase in serum creatinine level greater than 0.3 mg/dl and greater than 20% on day 1, 2, or 3 and on day 5, 6, or 7, is 7% vs 26% (p = .001). When only patients with preangiography azotemia are considered, the incidence of contrast-induced nephropathy for LOM vs HOM is 10% vs 41% (p = .017); for diabetic patients, regardless of preangiography creatinine level, the incidence is 10% vs 31% (p = .012). Although contrast-induced nephropathy may develop even in a patient with no risk factors who receives LOM, LOM is associated with a decreased incidence of this condition, to various degrees, depending on the presence of risk factors.

摘要

肾病是与传统高渗性造影剂(HOM)血管内给药相关的既定不良事件。此前尚未证明在临床环境中低渗性造影剂(LOM)的肾毒性较小。我们评估了在下肢血管造影中用LOM替代HOM以降低肾病发生率的能力。我们对造影剂肾病使用了多种定义(血清肌酐或血尿素氮水平在不同时期六种不同幅度的升高)。还评估了在包括已有肾功能不全和糖尿病在内的具有假定风险因素的患者中,LOM与HOM的肾毒性作用发生率。当考虑所有患者时,LOM与HOM的造影剂肾病发生率(定义为血清肌酐水平在第1、2或3天以及第5、6或7天升高大于0.3mg/dl且大于20%)分别为7%和26%(p = 0.001)。当仅考虑血管造影术前有氮质血症的患者时,LOM与HOM的造影剂肾病发生率分别为10%和41%(p = 0.017);对于糖尿病患者,无论血管造影术前肌酐水平如何,发生率分别为10%和31%(p = 0.012)。尽管即使在接受LOM且无风险因素的患者中也可能发生造影剂肾病,但根据风险因素的存在情况,LOM在不同程度上与该疾病发生率的降低相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验